Esperion Therapeutics (ESPR) Shares Outstanding (Weighted Average) (2012 - 2025)

Esperion Therapeutics has reported Shares Outstanding (Weighted Average) for 14 years, with the latest figure at $18.9 million in Q4 2025.

• For the quarter ending Q4 2025, Shares Outstanding (Weighted Average) fell 27.53% year-over-year to $18.9 million; the trailing twelve-month figure through Dec 2025 stood at $18.9 million (down 27.53% YoY), and the FY2025 full-year result was $18.9 million, down 27.53% from the prior year.
• Shares Outstanding (Weighted Average) for Q4 2025 stood at $18.9 million, down from $200.7 million in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $200.7 million in Q3 2025, with the low at $18.9 million in Q4 2025.
• Historically, Shares Outstanding (Weighted Average) has averaged $81.5 million across 5 years, with a median of $51.7 million in 2022.
• Annual changes were most pronounced in 2024 — Shares Outstanding (Weighted Average) plunged 74.71% — and 2025, when it jumped 669.95%.
• Esperion Therapeutics' Shares Outstanding (Weighted Average) stood at $28.9 million in 2021, then soared by 129.76% to $66.4 million in 2022, then surged by 55.26% to $103.1 million in 2023, then sank by 74.71% to $26.1 million in 2024, then dropped by 27.53% to $18.9 million in 2025.
• The last three Shares Outstanding (Weighted Average) figures came in at $18.9 million (Q4 2025), $200.7 million (Q3 2025), and $196.8 million (Q2 2025), per Business Quant data.